Andrea Tan
Stock Analyst at Goldman Sachs
(1.63)
# 3,324
Out of 5,182 analysts
47
Total ratings
39.02%
Success rate
-2.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $272.75 | +19.89% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $73.60 | +15.49% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $135.98 | +65.47% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $3.43 | +133.24% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $60.93 | -16.30% | 4 | May 5, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $8.12 | -26.11% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $7.03 | -71.55% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $44.11 | -95.47% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $4.16 | +476.92% | 2 | Aug 4, 2023 | |
| FATE Fate Therapeutics | Maintains: Sell | $10 → $4 | $1.31 | +205.34% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $520.09 | -27.90% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $14.12 | +466.57% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $272.75
Upside: +19.89%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $73.60
Upside: +15.49%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $135.98
Upside: +65.47%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $3.43
Upside: +133.24%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $60.93
Upside: -16.30%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $8.12
Upside: -26.11%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $7.03
Upside: -71.55%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $44.11
Upside: -95.47%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $4.16
Upside: +476.92%
Fate Therapeutics
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.31
Upside: +205.34%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $520.09
Upside: -27.90%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $14.12
Upside: +466.57%